SLG
NVO

Stanley-Laman Group’s Novo Nordisk NVO Stock Holding History

Stanley-Laman Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,531
Closed -$244K – 298
2025
Q2 		$244K Sell
3,531
-2,087
-37% -$142K 0.04% 262
2025
Q1 		$390K Buy
+5,618
New +$464K 0.06% 216
2024
Q4 		– Sell
-2,369
Closed -$282K – 293
2024
Q3 		$282K Buy
+2,369
New +$316K 0.04% 242

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stanley-Laman Group's NVO Position: Q3 2025 in Review

Stanley-Laman Group sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 3,531 shares — an estimated $244K sold.

Stanley-Laman Group first reported a position in NVO in Q3 2024 and held it in 3 quarters. The position peaked at $390K in Q1 2025. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Stanley-Laman Group reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Stanley-Laman Group sold 3,531 Novo Nordisk shares in Q3 2025, an estimated $244K.
  • Stanley-Laman Group first reported a position in Novo Nordisk in Q3 2024 and held it in 3 quarters.
  • Stanley-Laman Group's Novo Nordisk position peaked at $390K in Q1 2025.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Stanley-Laman Group's 13F filing for Q3 2025, filed 22 Oct 2025.